Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J8655 · per 0.5 MG

Oral netupitant, palonosetro

Products billed under this code include Akynzeo.

Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J8655

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Akynzeo Helsinn Therapeutics (U.S.), Inc. 69639-0101-01 1 $455.762

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $455.762 −$18.276 0.5 MG Oral netupitant, palonosetro v1, posted September 17, 2026
3Q26 $474.038 +$76.245 0.5 MG Oral netupitant, palonosetro v1, posted September 15, 2026
2Q26 $397.793 +$17.605 0.5 MG Oral netupitant, palonosetro v1, posted September 15, 2026
1Q26 $380.188 −$42.705 0.5 MG Oral netupitant, palonosetro v1, posted September 15, 2026
4Q25 $422.893 +$13.373 0.5 MG Oral netupitant, palonosetro v1, posted September 8, 2026
3Q25 $409.52 +$0.511 0.5 MG Oral netupitant, palonosetro v1, posted March 10, 2026
2Q25 $409.009 +$9.137 0.5 MG Oral netupitant, palonosetro v1, posted March 10, 2026
1Q25 $399.872 −$0.37 0.5 MG Oral netupitant, palonosetro v1, posted December 19, 2025
4Q24 $400.242 +$6.38 0.5 MG Oral netupitant, palonosetro v1, posted June 11, 2025
3Q24 $393.862 −$15.185 0.5 MG Oral netupitant, palonosetro v1, posted June 11, 2025
2Q24 $409.047 −$1.011 0.5 MG Oral netupitant, palonosetro v1, posted March 11, 2025
1Q24 $410.058 +$2.225 0.5 MG Oral netupitant, palonosetro v1, posted December 19, 2024
4Q23 $407.833 −$11.729 0.5 MG Oral netupitant, palonosetro v1, posted October 10, 2024
3Q23 $419.562 −$22.547 0.5 MG Oral netupitant, palonosetro v1, posted June 5, 2024
2Q23 $442.109 +$32.581 0.5 MG Oral netupitant, palonosetro v1, posted February 23, 2024
1Q23 $409.528 +$13.443 0.5 MG Oral netupitant, palonosetro v1, posted December 6, 2023
4Q22 $396.085 +$17.025 0.5 MG Oral netupitant, palonosetro v1, posted June 22, 2023
3Q22 $379.06 +$23.489 0.5 MG Oral netupitant, palonosetro v1, posted June 9, 2023
2Q22 $355.571 +$32.857 0.5 MG Oral netupitant, palonosetro v1, posted December 14, 2022
1Q22 $322.714 +$7.122 0.5 MG Oral netupitant, palonosetro v1, posted June 8, 2022
4Q21 $315.592 −$0.828 0.5 MG Oral netupitant, palonosetro v1, posted June 2, 2022
3Q21 $316.42 +$12.291 0.5 MG Oral netupitant, palonosetro v1, posted June 2, 2022
2Q21 $304.129 +$33.479 0.5 MG Oral netupitant, palonosetro v1, posted March 1, 2022
1Q21 $270.65 – 0.5 MG Oral netupitant, palonosetro v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files